# 🧬 Virtual Biotech

> **An AI-native biotech organization for drug discovery and development.**
> From **Target → Molecule → Preclinical → Clinical → BD**, coordinated by specialized AI agents.

Virtual Biotech is an open-source project exploring what happens when we move from **one AI assistant** to an **AI-native biotech organization**.

Instead of building a single chatbot that answers questions about drug development, Virtual Biotech organizes specialized AI agents into teams that collaborate like a real biotech company.

---

## 🚀 Vision

The traditional biotech model looks like:

```text
Human Scientists
       ↓
Research Teams
       ↓
Departments
       ↓
Program Teams
       ↓
Drug Candidate
       ↓
Clinical Development
```

Virtual Biotech explores a new model:

```text
                    ┌─────────────────────┐
                    │   AI Chief Scientist│
                    │        / CSO        │
                    └──────────┬──────────┘
                               │
        ┌──────────────────────┼──────────────────────┐
        ↓                      ↓                      ↓
┌───────────────┐      ┌───────────────┐      ┌───────────────┐
│ Target &      │      │ Discovery &   │      │ Clinical &    │
│ Biology Team  │      │ Molecule Team │      │ Translational │
└───────────────┘      └───────────────┘      └───────────────┘
        ↓                      ↓                      ↓
   Target ID              Molecule Design       Clinical Data
   Genetics               ADME / PK             Trial Design
   Disease Biology        Developability        Biomarkers
        │                      │                      │
        └──────────────────────┼──────────────────────┘
                               ↓
                    ┌─────────────────────┐
                    │ Program Management  │
                    │   & Decision Agent  │
                    └──────────┬──────────┘
                               ↓
                         Drug Pipeline
```

The goal is not to replace scientists.

The goal is to explore how **humans + AI agents can operate a biotech company together**.

---

# 🎯 What We Are Building

Virtual Biotech is designed around the complete drug development lifecycle:

```text
Target
  ↓
Target Validation
  ↓
Hit / Lead Discovery
  ↓
Molecule Design
  ↓
In Silico Evaluation
  ↓
Preclinical
  ↓
IND Strategy
  ↓
Clinical Development
  ↓
Clinical Data Analysis
  ↓
Regulatory Strategy
  ↓
Business Development
```

Each stage can be handled by specialized agents, tools, and workflows.

---

# 🤖 AI Organization

Instead of one general-purpose agent, Virtual Biotech uses specialized agents.

## 🧠 Executive / CSO Office

### Chief Scientific Officer Agent

Responsible for:

* Defining research strategy
* Prioritizing programs
* Reviewing scientific evidence
* Coordinating research teams
* Challenging assumptions
* Making program-level recommendations

### Program Management Agent

Responsible for:

* Tracking development programs
* Monitoring milestones
* Identifying bottlenecks
* Comparing competing programs
* Maintaining program memory

---

# 🔬 Target & Biology Division

### Target Discovery Agent

Analyzes:

* Literature
* Genetics
* Disease biology
* Human datasets
* Competitive pipelines
* Target validation evidence

### Target Validation Agent

Evaluates:

* Genetic validation
* Pharmacological validation
* Human evidence
* Biomarker relationships
* Safety liabilities
* Competitive differentiation

### Disease Biology Agent

Builds disease-mechanism maps and identifies:

* Pathways
* Cell types
* Disease drivers
* Biomarkers
* Resistance mechanisms

---

# 🧪 Drug Discovery Division

### Molecule Design Agent

Supports:

* Small-molecule discovery
* Structure-based design
* Virtual screening
* Molecular optimization
* SAR analysis

### Biologics Agent

Supports:

* Antibody design
* Bispecific antibodies
* Multispecific antibodies
* Protein engineering
* ADC concepts

### Developability Agent

Evaluates:

* ADME
* PK
* Solubility
* Stability
* Immunogenicity
* Manufacturability

---

# 🐁 Preclinical Division

Agents analyze:

* In vitro studies
* In vivo studies
* PK/PD
* Toxicology
* Biomarkers
* Translational evidence

The objective is to answer:

> **Is this molecule ready to become a development candidate?**

---

# 🏥 Clinical Development Division

### Clinical Trial Agent

Analyzes:

* ClinicalTrials.gov
* Trial design
* Inclusion / exclusion criteria
* Endpoints
* Patient populations
* Competitor trials

### Clinical Data Agent

Analyzes:

* ORR
* CR
* PR
* PFS
* OS
* Safety
* Biomarkers
* Subgroup analysis

### Clinical Strategy Agent

Supports:

* Phase I strategy
* Phase II design
* Phase III strategy
* Dose selection
* Patient segmentation
* Competitive positioning

---

# 💰 BD & Competitive Intelligence

Virtual Biotech also treats **business development as part of drug development**.

### Competitive Intelligence Agent

Tracks:

* Competitor pipelines
* Clinical milestones
* Trial readouts
* Publications
* Patents
* Financing
* M&A
* Licensing deals

### BD Agent

Evaluates:

* Licensing opportunities
* Partnering targets
* Asset valuation
* Strategic fit
* Pipeline gaps

---

# 🧠 Agent Architecture

The system is designed around a hierarchical architecture:

```text
                       Human Scientists
                              │
                              ↓
                     ┌─────────────────┐
                     │   AI CSO Agent  │
                     └────────┬────────┘
                              │
             ┌────────────────┼────────────────┐
             ↓                ↓                ↓
        Biology Team     Discovery Team    Clinical Team
             │                │                │
        ┌────┴────┐      ┌────┴────┐      ┌────┴────┐
        ↓         ↓      ↓         ↓      ↓         ↓
     Target    Disease  Molecule   ADME   Clinical  Data
     Agent     Agent    Agent      Agent  Agent     Agent
             │                │                │
             └────────────────┼────────────────┘
                              ↓
                     Evidence / Memory
                              ↓
                       Decision Engine
                              ↓
                        Human Review
```

---

# 🔎 Evidence First

Virtual Biotech is designed around an **evidence-first** principle.

Agents should distinguish between:

* Published evidence
* Clinical evidence
* Computational prediction
* Internal analysis
* Hypothesis
* Speculation

Every important conclusion should ideally include:

```text
Claim
 ↓
Evidence
 ↓
Source
 ↓
Confidence
 ↓
Alternative explanation
```

The system should never confuse an AI-generated hypothesis with experimental evidence.

---

# 📚 Knowledge Layer

Potential data sources include:

### Scientific Literature

* PubMed
* Europe PMC
* bioRxiv
* medRxiv

### Clinical Trials

* ClinicalTrials.gov
* WHO ICTRP
* EU Clinical Trials Information System

### Drug & Target Knowledge

* ChEMBL
* DrugBank
* Open Targets
* UniProt
* STRING

### Genomics

* GTEx
* TCGA
* GWAS Catalog
* DepMap

### Competitive Intelligence

* SEC filings
* Company pipelines
* Investor presentations
* Scientific conferences
* Patents

---

# 🛠️ Tools

Agents can access specialized tools rather than relying only on LLM knowledge.

Example:

```text
LLM
 │
 ├── Literature Search
 ├── Clinical Trial Search
 ├── PubMed
 ├── ChEMBL
 ├── Open Targets
 ├── ClinicalTrials.gov
 ├── Molecular Modeling
 ├── Python / Data Science
 ├── R
 └── Internal Knowledge Base
```

The architecture is intended to support **MCP-compatible tools** where appropriate.

---

# 🧩 Example Workflow

## Example: Oncology Target Evaluation

A researcher asks:

> Should we develop a drug against Target X for pancreatic cancer?

The Virtual Biotech could execute:

```text
CSO Agent
   ↓
Target Discovery Agent
   ↓
Disease Biology Agent
   ↓
Genetics Agent
   ↓
Clinical Trial Agent
   ↓
Competitive Intelligence Agent
   ↓
Safety Agent
   ↓
Molecule Discovery Agent
   ↓
Program Strategy Agent
   ↓
CSO Review
   ↓
Human Scientist
```

The final output could contain:

```text
1. Target rationale
2. Human genetic evidence
3. Biological mechanism
4. Existing clinical evidence
5. Competitor landscape
6. Safety considerations
7. Biomarker strategy
8. Potential modalities
9. Development risks
10. Recommended experiments
11. Go / No-Go considerations
```

The system provides **decision support**, not autonomous scientific authority.

---

# 🏗️ Project Structure

A potential project structure:

```text
virtual-biotech/
│
├── agents/
│   ├── cso/
│   ├── target/
│   ├── biology/
│   ├── molecule/
│   ├── preclinical/
│   ├── clinical/
│   ├── regulatory/
│   ├── competitive/
│   └── bd/
│
├── tools/
│   ├── literature/
│   ├── clinical_trials/
│   ├── chemistry/
│   ├── genomics/
│   └── analytics/
│
├── workflows/
│   ├── target_validation/
│   ├── drug_discovery/
│   ├── preclinical/
│   └── clinical/
│
├── knowledge/
│   ├── targets/
│   ├── drugs/
│   ├── trials/
│   └── companies/
│
├── memory/
│
├── evaluation/
│
├── configs/
│
├── tests/
│
├── docs/
│
├── examples/
│
└── README.md
```

---

# ⚙️ Technology Stack

The initial implementation can use:

* **Python**
* **LLMs**
* **LangGraph / agent orchestration**
* **MCP**
* **FastAPI**
* **PostgreSQL**
* **Vector Database**
* **Python scientific ecosystem**
* **Docker**

The architecture is intentionally modular so individual components can be replaced.

---

# 📊 Evaluation

A Virtual Biotech should not be evaluated only by whether an LLM produces convincing answers.

We should evaluate:

### Scientific Accuracy

Does the agent correctly interpret the evidence?

### Retrieval Quality

Can it find the relevant papers, trials, targets and molecules?

### Reasoning

Can it connect evidence across different domains?

### Reproducibility

Can another researcher reproduce the analysis?

### Decision Quality

Does the system identify relevant risks and uncertainties?

### Human Evaluation

Would an experienced scientist consider the analysis useful?

---

# 🔐 Human-in-the-Loop

Virtual Biotech is **not designed to autonomously make irreversible scientific or clinical decisions**.

Human experts remain responsible for:

* Scientific judgment
* Experimental validation
* Clinical decisions
* Regulatory decisions
* Patient safety
* Investment decisions

AI agents provide analysis, hypotheses, prioritization and decision support.

---

# 🌎 Long-Term Vision

The long-term goal is to explore a new paradigm:

> **What does a biotech company look like when intelligence becomes software?**

Today:

```text
1 Scientist
   ↓
1 Team
   ↓
1 Department
   ↓
1 Company
```

Tomorrow:

```text
Human Scientists
       +
AI Agents
       ↓
AI-Native Teams
       ↓
AI-Native Departments
       ↓
AI-Native Biotech
```

The fundamental question is no longer:

> **"Can AI discover a drug?"**

It becomes:

> **"Can we build an organization in which humans and AI systematically discover, develop, and evaluate drugs together?"**

---

# 🧪 Current Status

🚧 **Early-stage research project**

Current focus:

* [ ] Agent architecture
* [ ] CSO agent
* [ ] Target discovery agent
* [ ] Clinical trial intelligence
* [ ] Competitive intelligence
* [ ] Literature retrieval
* [ ] Biomedical knowledge graph
* [ ] MCP tool integration
* [ ] Multi-agent workflows
* [ ] Evaluation framework
* [ ] Human-in-the-loop interface

---

# 🤝 Contributing

Contributions are welcome.

Areas where contributors can help:

* Agent development
* Biomedical data integration
* Drug discovery workflows
* Clinical development
* MCP tools
* Evaluation
* UI/UX
* Scientific validation

Please open an issue before starting major architectural changes.

---

# ⚠️ Disclaimer

Virtual Biotech is an experimental research and software project.

It is intended for **research, education, and decision support**.

Outputs generated by AI agents should not be treated as medical advice, clinical recommendations, regulatory advice, or validated scientific conclusions without appropriate expert review and experimental validation.

---

# 📜 License

License: **TBD**

---

## ⭐ Vision

**From AI assistant → AI scientist → AI team → AI biotech.**

**Target → Molecule → Preclinical → Clinical → BD.**

Building the operating system for the next generation of biotech.
